Cantor Fitzgerald Boosts Cypherpunk Technologies (NASDAQ:CYPH) Price Target to $4.90

Key Points

• Cantor Fitzgerald raised Cypherpunk Technologies’ price target to $4.90 from $1.60 and maintained an “overweight” rating, implying 100% upside from the prior close.
• Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus “Hold” rating and a $4.90 average price target.
• Shares opened at $2.45, while the company reported quarterly earnings of $0.18 per share; institutional investors own 30.46% of the stock, and a director recently sold 20,000 shares.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) had its price objective boosted by investment analysts at Cantor Fitzgerald from $1.60 to $4.90 in a research report issued on Thursday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Cantor Fitzgerald's price target points to a potential upside of 100.00% from the stock's previous close.

A number of other equities analysts have also issued reports on the company. Weiss Ratings raised Cypherpunk Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, August 17th. Wall Street Zen upgraded Cypherpunk Technologies from a "sell" rating to a "hold" rating in a research report on Saturday, July 4th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Cypherpunk Technologies has a consensus rating of "Hold" and an average price target of $4.90.

Cypherpunk Technologies Stock Performance

NASDAQ CYPH opened at $2.45 on Thursday. The company has a 50-day simple moving average of $1.05 and a 200-day simple moving average of $0.91. Cypherpunk Technologies has a one year low of $0.28 and a one year high of $3.70. The firm has a market capitalization of $264.01 million, a PE ratio of 4.38 and a beta of 0.33.

Cypherpunk Technologies (NASDAQ:CYPH - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.18 earnings per share for the quarter.

Insider Transactions at Cypherpunk Technologies

In other news, Director Thomas Dietz sold 20,000 shares of Cypherpunk Technologies stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $1.72, for a total transaction of $34,400.00. Following the transaction, the director directly owned 132,500 shares in the company, valued at approximately $227,900. This trade represents a 13.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.50% of the company's stock.

Institutional Trading of Cypherpunk Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in CYPH. Millennium Management LLC bought a new stake in Cypherpunk Technologies during the fourth quarter worth approximately $37,000. LPL Financial LLC acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at $38,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at $44,000. Sequoia Financial Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter worth $56,000. Finally, HighTower Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter worth $59,000. 30.46% of the stock is currently owned by institutional investors.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.